Metastatic in Biological Technology

Poniard Pharmaceuticals Reports Second Quarter 2009 Financial Results and Provides a Corporate Update

... of picoplatin for the first-line treatment of metastatic CRC at the 2009 American Society of Clinical ... for the first-line treatment of patients with metastatic CRPC at the 2009 ASCO Annual Meeting. The updated ... prednisone is active as first-line therapy for metastatic CRPC as demonstrated by several endpoints, ...

Sanofi-aventis Announces Second Quarter 2009 Results

... as a first line treatment for women with metastatic breast cancer, based on the results of the AVADO ... an adjuvant and as a first-line treatment in the metastatic phase, achieved second-quarter growth of 10.0% in ... in association with chemotherapy in women with metastatic triple negative breast cancer (mTNBC), i.e. with ...

Monitoring Circulating Tumor Cells With the CellSearch(R) System Can Predict Prognosis in Metastatic Breast Cancer

... the prognosis and survival in patients with metastatic breast cancer (MBC), according to a newly ... the patient's blood. "Measuring CTCs in metastatic breast cancer patients provides oncologists with ... test in therapeutic monitoring of patients with metastatic disease." Study Design A retrospective ...

New Report Just Published: World Prostate Cancer Therapeutics Market Report

... Unveils Results of PCK3145 in Patients with metastatic Prostate Cancer II-54 Peregrine ... Unveils New Therapeutic Cancer Vaccine For metastatic Prostate Cancer II-64 PNNL and IsoRay ... Unveils Results of PCK3145 in Patients with metastatic Prostate Cancer III-69 Ambrilia Reveals ...

OncoGenex Pharmaceuticals Completes Amendment to Phase 3 Special Protocol Assessment for Confirming Survival Benefit in Patients Receiving OGX-011 with First-Line Docetaxel for Metastatic Prostate Cancer

... controlled, international study in 800 men with metastatic CRPC who are in need of first-line chemotherapy. ... median overall survival in patients with advanced metastatic prostate cancer who were treated with OGX-011 ... two Phase 3 registration trials with OGX-011 in metastatic castrate resistant prostate cancer, subject to ...

Oncothyreon announces initiation of Phase 3 trial of Stimuvax in breast cancer

... receptor-positive, locally advanced, recurrent or metastatic breast cancer. Stimuvax is an investigational ... non-resectable locally advanced, recurrent or metastatic breast cancer receiving hormonal therapy will be ... for patients with hormone receptor positive metastatic breast cancer." "The initiation of the STRIDE ...

AEterna Zentaris Discloses Preliminary Phase 2 Trial Results for Perifosine in Combination with Radiotherapy for Non-Small Cell Lung Cancer

... the disease targets of both multiple myeloma and metastatic colon cancer where, unlike the non-small cell ... positive Phase 2 data for multiple myeloma and metastatic colon cancer were presented at ASH and ASCO ... agent use of perifosine in patients with advanced metastatic renal cancer and in combination with capecitabine ...

Delcath Systems Granted Third Orphan Drug Designation

... its proprietary treatment method for primary and metastatic cancers to the liver, announced today that the ... for the treatment of neuroendocrine tumors metastatic to the liver. The trial is treating patients ... drug melphalan for the treatment of patients with metastatic cutaneous melanoma ...

Micromet Presents Update at ASCO 2009 on a Phase 1b Combination Study of Adecatumumab and Docetaxel

... the chemotherapeutic docetaxel in patients with metastatic breast cancer (MBC) at the annual meeting of the ... in combination with docetaxel for patients with metastatic breast cancer: Results of a multicenter phase Ib ... antibody, as monotherapy in patients with metastatic breast cancer. Annals of Oncology, in press. ...

OncoGenex Pharmaceuticals Announces OGX-011 Treatment Provides Survival Benefit in Randomized Phase 2 Trial in Advanced Metastatic Prostate Cancer

... in combination with second-line treatment of metastatic castrate resistant prostate cancer showing better ... Phase 3 registration trials with OGX-011 in metastatic castrate resistant prostate cancer, subject to ... from the FDA for the treatment of progressive metastatic prostate cancer in combination with docetaxel. ...

OncoGenex Pharmaceuticals Announces Release of Two ASCO Abstracts: Impact of OGX-011 on Survival in Randomized Phase 2 Trial and Phase 1 Safety Data for OGX-427

... docetaxel/prednisone in patients with metastatic castration resistant prostate ... in combination with second-line treatment of metastatic castrate resistant prostate cancer showing better ... Phase 3 registration trials with OGX-011 in metastatic castrate resistant prostate cancer, subject to ...

Lilly Set to Unveil More Than 50 Studies at ASCO 2009

... cisplatin in patients (pts) with advanced or metastatic biliary tract cancer (ABC): Results of a ... locally advanced (Stage IIIA or Stage IIIB) or metastatic (Stage IV or cancer that has spread) non-small ... II or Stage III when surgery is not an option) or metastatic (Stage IV) adenocarcinoma of the pancreas. GEMZAR ...

Eric D. Whitman, MD to Present on the Delcath PHP System(TM) at the 7th World Congress on Melanoma

... Hepatic Perfusion for Cutaneous and Uveal metastatic Melanoma , will discuss his experience with the ... of Delcath's multi-center Phase III trial for metastatic melanoma, currently enrolling at twelve leading ... of melphalan to the liver to treat patients with metastatic cutaneous and ocular melanoma who have ...

OncoGenex Receives Confirmation from FDA on the Design of a Second Phase 3 Trial Evaluating OGX-011 for the Treatment of Advanced Prostate Cancer

... international trial in approximately 300 men with metastatic CRPC who responded to first-line docetaxel ... in this trial. "Patients with pain due to metastatic prostate cancer generally require narcotic ... Phase 2 trial in first-line treatment of metastatic castrate resistant prostate cancer, in which the ...

Poniard Pharmaceuticals Presents Final Results of Phase 1 Study of Picoplatin in Patients with Metastatic Colorectal Cancer

... study of picoplatin in patients with metastatic colorectal cancer (CRC). Results demonstrated ... to oxaliplatin for the first-line treatment of metastatic CRC. Patient enrollment was completed in May 2008. "Several treatment options for metastatic CRC have been introduced in the last decade and ...

BioVex Commences OncoVEX (GM-CSF) Phase 3 Trial in Metastatic Melanoma

... treatment options for patients with recurrent or metastatic melanoma are currently very limited, with no ... of un-injected visceral deposits. About metastatic Melanoma According to the National Cancer ... survival for patients diagnosed with late-stage metastatic disease, or Stage IV disease, is six to nine ...

BioVex Raises $40 Million in First Close of Series F Financing

... OncoVEX GM-CSF in a Phase II study in metastatic melanoma, the funds will be used to commence a ... with unresectable Stage IIIc and Stage IV metastatic melanoma. The trial was designed to measure ... the immune system to destroy un-injected metastatic deposits. Both modes of action have been clearly ...

Sopherion Therapeutics Announces Completion of Enrollment in Phase III Study of Myocet in Metastatic Breast Cancer

... liposomal doxorubicin (Myocet(TM)) in metastatic HER-2-overexpressing breast cancer. This is a ... pivotal Phase III study in 363 patients who have metastatic HER-2-overexpressing breast cancer. Eligibility criteria included no prior chemotherapy for metastatic disease, nor any trastuzumab, anthracyclines or ...

Micromet, Inc. To Regain Rights to Blinatumomab in North America; Reports Financial Results for the Fourth Quarter and Full Year ended December 31, 2008

... of adecatumumab with docetaxel in late stage metastatic breast cancer patients at the European Society ... adecatumumab with docetaxel in late stage metastatic breast cancer patients at the annual meeting of ... EpCAM-targeting BiTE antibody, in patients with metastatic gastrointestinal and lung cancers at the joint ...

OncoGenex Reports Financial Results for Fourth Quarter and Fiscal Year 2008 and Provides Outlook for 2009

... control arm") for first-line treatment of metastatic CRPC. The median survival was 27.5 months ... docetaxel was approved for treatment of metastatic CRPC by the FDA based on a survival ... first-line docetaxel to mitoxantrone in metastatic CRPC, referred to as the TAX 327 Study, ...

Poniard Pharmaceuticals Announces New Efficacy and Safety Data from a Phase 2 Picoplatin Trial in Patients with Prostate Cancer

... Docetaxel/Prednisone as First-Line Therapy for metastatic Castration-Resistant Prostate Cancer - - ... and prednisone as first-line therapy for metastatic castration-resistant prostate cancer (CRPC). ... combination is active as first-line therapy for metastatic CRPC (also known as hormone-refractory prostate ...

Sopherion Therapeutics, LLC Announces Publication of Phase I/II Myocet(R) (Nonpegylated Liposomal Doxorubicin) Data in Advanced Breast Cancer Patients

... advanced nonoperable breast cancer (LABC) or metastatic breast cancer (MBC). Sixty-nine adult ... cancer, while it exceeded 21 months in those with metastatic disease. The most common adverse events included ... an ongoing registration trial in patients with metastatic HER-2-overexpressing breast cancer, sponsored by ...

OncoGenex Provides Update on Two-Year Survival Data from Ongoing Phase 1/2 Clinical Trial of OGX-011 in Non-Small Cell Lung Cancer

... Phase 2 Study in first-line treatment of metastatic castrate resistant prostate cancer, in which the ... OGX-011 Phase 2 data in second-line treatment of metastatic castrate resistant prostate cancer showing better ... Phase 3 registration studies with OGX-011 in metastatic castrate resistant prostate cancer, subject to ...

REXIN-G Shrinks Metastatic Tumors and Triples Survival Time in Chemotherapy-Resistant Pancreatic Cancer: Analysis of a U.S. Phase I/II Clinical Trial (Proceedings of ASCO GI Symposium 2009)

... and efficacy of Rexin-G in chemotherapy-resistant metastatic pancreatic cancer (ASCO GI Symposium, #249; Sant ... for Rexin-G bioactivity in the treatment of metastatic pancreatic cancer. The present study confirms ... to seek out and destroy both primary tumors and metastatic cancers that have spread throughout the body. ...

Poniard Pharmaceuticals Announces Positive Tumor Response and Neuropathy Data from Phase 2 Clinical Trial of Picoplatin in Metastatic Colorectal Cancer

... 2 clinical trial of picoplatin in patients with metastatic colorectal cancer (CRC). Results continue to ... have similar anti-tumor activity in first-line metastatic CRC. Net sales in 2007 in the US for Eloxatin ... to oxaliplatin for the first-line treatment of metastatic CRC in 101 patients who have not received prior ...

First Patient Dosed in Phase 2 Clinical Trial of NKTR-102 in Ovarian Cancer

... the KRAS gene mutation, and a Phase 2 study in metastatic breast cancer. Nektar has also ... or every 21 days). Patients include those with metastatic breast cancer with prior taxane treatment, those ... platinum-resistant ovarian cancer and those with metastatic cervical cancer. The trials are designed to ...

Poniard Pharmaceuticals to Present Data from Phase 2 Clinical Trials of Picoplatin in Colorectal and Prostate Cancers

... its Phase 2 trial of picoplatin in patients with metastatic colorectal cancer at ASCO's 2009 Gastrointestinal ... prednisone in first-line treatment of metastatic hormone refractory prostate cancer ... in small cell lung cancer and Phase 2 trials in metastatic colorectal and hormone-refractory prostate ...

Oncology Biomarker KRAS to be Discussed at FDA Panel Meeting

... gene as a predictive biomarker in patients with metastatic colorectal cancer (mCRC) treated with ... pre-treatment work-up for patients diagnosed with metastatic colorectal cancer. Further, the guidelines ... growth factor receptor- (EGFr) expressing metastatic colorectal cancer after disease progression on, ...

Algeta Appoints Andrew Kay as President and Chief Executive Officer

... II trial completed in 2007 involving 64 men with metastatic HRPC, Alpharadin was shown to increase life ... role in the treatment of other high-incidence metastatic cancers. Algeta began its pivotal phase ... trial is evaluating Alpharadin in metastatic HRPC with overall survival as the primary ...

Oncolytics Biotech Inc.'s REOLYSIN(R) Exceeds Primary Statistical Endpoint in U.S. Phase 2 Sarcoma Study

... that REOLYSIN(R) is active in various types of metastatic sarcoma, and that late-stage clinical trials are ... in patients with bone and soft tissue sarcomas metastatic to the lung. REOLYSIN(R) is delivered ... patients must have a bone or soft tissue sarcoma metastatic to the lung deemed by their physician to be ...

Lilly Highlights Transformation Strategy for Wall Street, Reviews Robust Pipeline and Sets 2009 Financial Guidance

... receptor. Phase II studies are underway for metastatic melanoma, renal, liver, ovarian, prostate and non-small cell lung cancers. metastatic breast cancer is in Phase III testing, while ... (EGFR). It is currently in Phase II studies for metastatic colorectal cancer with one or more Phase III ...

3SBio Inc. Files for SFDA Approval of NuLeusin

... of NuLeusin for the treatment of late stage metastatic renal cell carcinoma. If approved, NuLeusin is ... oncologists to treat patients with late stage metastatic renal cell carcinoma. Upon approval, we believe ... NuLeusin to be an effective treatment for metastatic renal cell carcinoma with improved safety ...

Data Presented at Cancer Molecular Markers Meeting Suggests Clinical Benefit for Integrating New Molecular Tests

... (IHC) to determine the origin of metastatic cancer at the second annual ASCO-NCI-EORTC ... attempting to determine the tissue of origin for metastatic tumors. In the poster presentation, entitled "A Meta-Analysis of the Use of IHC Testing in metastatic Disease: The Need for Integration of ...

Monogram Announces 2008 Third Quarter Financial Results

... as a predictor of Herceptin response in both the metastatic and adjuvant settings. Preliminary results of one such study in metastatic breast cancer were presented by collaborators ... recently announced the initiation of a study in metastatic breast cancer with the Dana Farber Cancer ...

Poniard Announces Positive Incremental Efficacy and Safety Data from Phase 2 Picoplatin Trial in Patients With Metastatic Colorectal Cancer

... 2 clinical trial of picoplatin in patients with metastatic colorectal cancer (CRC). The expanded and updated ... have similar anti-tumor activity in first-line metastatic CRC. "Picoplatin appears to be an active ... a neuropathy-sparing first-line therapy for metastatic colorectal cancer," said Robert De Jager, M.D., ...

Targeting Metastatic Cancer From the Inside: Epeius Biotech Reveals a New Generation of Tools for Medical Gene Delivery

... The latest scientific paper, entitled "Targeting metastatic cancer from the inside: A new generation of ... medicine, specifically for patients with metastatic cancer. Based on recent breakthroughs in ... to seek out and accumulate in primary and metastatic lesions that have spread throughout the ...

Lilly to Acquire ImClone Systems in $6.5 Billion Transaction

... growth. Phase II studies are underway for metastatic melanoma, renal, liver, ovarian and prostate cancers. metastatic breast cancer is in Phase III testing, while ... It is currently in Phase II studies for metastatic colorectal cancer with one or more Phase III ...

Epeius Biotechnologies' Lead Product, Rexin-G for Metastatic Cancer, Aptly Highlighted by National Cancer Institute Journal

... that Rexin-G, its lead product in development for metastatic cancer, has been highlighted in a recent NEWS ... and single-agent efficacy in several types of metastatic cancers that were refractory to standard ... and accumulating in primary tumors and metastatic tissues that have spread throughout the body. ...

/R E P E A T -- Oncolytics Biotech Inc. Announces U.S. Phase 2 Combination Clinical Trial for Non-Small Cell Lung Cancer Patients with K-RAS or EGFR-Activated Tumours/

... trial. Eligible patients include those with metastatic or recurrent NSCLC with K-RAS or EGFR-activated ... not received chemotherapy treatment for their metastatic or recurrent disease. Patients must ... with paclitaxel and carboplatin in patients with metastatic or recurrent NSCLC with K-RAS or EGFR-activated ...

Oncolytics Biotech Inc. Announces U.S. Phase 2 Combination Clinical Trial for Non-Small Cell Lung Cancer Patients with K-RAS or EGFR-Activated Tumours

... trial. Eligible patients include those with metastatic or recurrent NSCLC with K-RAS or EGFR-activated ... not received chemotherapy treatment for their metastatic or recurrent disease. Patients must ... with paclitaxel and carboplatin in patients with metastatic or recurrent NSCLC with K-RAS or EGFR-activated ...